[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bradycardia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bradycardia":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,49,88,115,146,173,195,215,241,263,290,321,354,378,407,426,455,478,499,521,542,574,593,615,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100623159","biostreamcsp-study-100623159",false,"NCT07393009","BIO|STREAM.CSP Study","Observation of Clinical Routine Care for Patients Implanted With BIOTRONIK Devices Used for Conduction System Pacing (CSP)","Inclusion Criteria:\n\n* Guideline indication for pacemaker or cardiac resynchronization therapy with or without defibrillation function (CRT-P\u002F-D)\n* Patient is intended for a de novo implantation and LBBAP therapy with an investigational generator and an investigational lead OR has just been implanted with an investigational generator and an investigational lead positioned permanently deep within the intraventricular septum and has not yet been discharged from the hospital OR transitions from the BIO\\|MASTER.CSP study\n* Ability to understand the nature of the study\n* Ability and willingness to perform all follow-up visits\n* Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring concept\n\nExclusion Criteria:\n\n* Planned dation from intended use\n* Planned for cardiac surgical procedures, heart transplantation or interventional measures other than the study procedure within one year after enrollment\n* Life-expectancy less than 12 months\n* Pregnant or breast feeding\n* Age less than 18 years\n* Participation in an interventional clinical investigation, except for submodules within this study.","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","4 Years","OBSERVATIONAL","The registry is designed to assess outcome, performance and residual safety aspects of BIOTRONIK products which are used in the context of CSP based on long-term data from an unselected, real-life clinical set-up.",[26,27,28,29,30,31,32],"Cardiac Pacing","Cardiac Pacemaker","Implantable Cardioverter Defibrillator","Cardiac Resynchronization Therapy Devices","Bradycardia","Tachycardia","Heart Failure",[34,35],"Conduction system pacing (CSP)","Left bundle branch area pacing (LBBAP)","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-29","ACTUAL",{"date":42,"type":40},"2026-05-25",{"date":44,"type":21},"2033-02-01",{"name":46,"class":47},"Biotronik SE & Co. KG","INDUSTRY",40,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100644473","comparison-of-focal-cryoablation-vs-radiofrequency-cardioneuroablation-for-bradyarrhythmias-100644473","NCT07671898","Comparison of Focal Cryoablation vs. Radiofrequency Cardioneuroablation for Bradyarrhythmias","Prospective Non-Randomized Comparison of Point-by-Point Cryoablation Using Freezor™ Xtra Versus Radiofrequency Ablation Using TactiFlex™ SE of Parasympathetic Ganglia (Cardioneuroablation) in Patients With Vagally-Mediated Bradyarrhythmias","CRYO-CNA vs RF","Inclusion Criteria:\n\n* Age 18 to 60 years;\n* Symptomatic bradycardia (sinus bradycardia or bradycardia due to atrioventricular block, including transient);\n* Severe asymptomatic sinus bradycardia (heart rate less than 30 beats per minute);\n* Transient second- or third-degree atrioventricular block;\n* Persistent second-degree atrioventricular block;\n* Rhythm pauses greater than 6 seconds;\n* Recurrent syncope or presyncope with documented association with bradycardia (without trauma);\n* Positive response to atropine (heart rate increase ≥25% from baseline or \\>90 beats per minute) OR positive response to exercise (heart rate increase ≥25% from baseline or \\>90 beats per minute, OR conversion of second- or third-degree atrioventricular block to first-degree block or complete normalization of atrioventricular conduction during sinus rhythm);\n\nExclusion Criteria:\n\n* Chronic antiarrhythmic drug therapy (ongoing);\n* Presence of implanted pacemaker, cardiac resynchronization therapy device, or implantable cardioverter-defibrillator;\n* Bradyarrhythmia secondary to medications;\n* Bradyarrhythmia secondary to electrolyte imbalance (hyperkalemia);\n* Bradyarrhythmia secondary to hypothyroidism;\n* Bradyarrhythmia secondary to obstructive sleep apnea syndrome;\n* Absence of response to pharmacological denervation (no heart rate increase after atropine administration up to maximum dose of 0.2 mg\u002Fkg);\n* Clinically significant coronary artery disease;\n* Post-myocardial infarction cardiosclerosis;\n* Hemodynamically significant congenital heart disease (including surgically corrected);\n* Stable ventricular tachycardia in the setting of bradycardia;\n* History of stroke or transient ischemic attack;\n* Prior open-heart surgery;\n* Prior catheter-based coronary artery intervention or percutaneous coronary intervention;\n* Pregnancy or breastfeeding; Age less than 18 years Age greater than 60 years","60 Years",{"count":59,"type":21},60,"INTERVENTIONAL",[62],"NA","Bradyarrhythmias are conditions where the heart beats too slowly, causing symptoms like dizziness, fainting, and fatigue. In some patients, these slow heart rhythms are caused by overactivity of the vagus nerve (the part of the nervous system that slows the heart down).\n\nCardioneuroablation (CNA) is a catheter-based procedure that targets and reduces the effect of these overactive nerves on the heart. It is an alternative to permanent pacemaker implantation, especially for younger patients.\n\nTraditionally, CNA is performed using radiofrequency (RF) energy to create small burns in specific areas of the heart. This study investigates whether focal cryoablation (freezing technology using the Freezor™ Xtra catheter) is as safe and effective as standard RF ablation for CNA.\n\nThis is a prospective, non-randomized study. Participants will receive either RF ablation (N=30) or cryoablation (N=30). The study will evaluate the recurrence of slow heart rhythms and fainting episodes, as well as any complications, over 12 months of follow-up.",[30,65,66,67],"Syncope, Vasovagal","Sick Sinus Syndrome","Atrioventricular Block",[69,70,71,72,73,74,75,76,66,67],"Cardioneuroablation,","Cryoablation","Radiofrequency Ablation","Ganglionated Plexi","Parasympathetic Nervous System","Bradyarrhythmias","Functional Bradycardia","Vasovagal Syncope","2026-06-22",{"date":79,"type":40},"2026-06-26",{"date":81,"type":40},"2024-09-01",{"date":83,"type":21},"2028-12-25",{"name":85,"class":86},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",1,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":60,"phases":97,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100602042","biotronik-investigation-of-the-liviq-leadless-pacemaker-system-100602042","NCT07118358","BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System","BIO-LivIQ","Inclusion criteria:\n\n1. Class I or Class II indication for ventricular pacing (VVI\u002FVDD) according to applicable guidelines\n2. Age is greater than or equal to 18 years at time of consent\n3. Able to understand the nature of the study and provide written informed consent\n4. Able and willing to complete all study requirements, including completion of all planned in-office study visits, for the expected duration of follow-up\n\nExclusion criteria:\n\n1. AV block with a ventricular escape rhythm ≤ 30 bpm at time of consent Note: Restriction removed after early safety phase objectives are met\n2. Femoral venous anatomy that is unable to accommodate the introducer or the cardiac anatomy does not allow a leadless pacemaker in the right ventricle\n3. Morbid obesity which may prevent the LivIQ device from obtaining telemetry communication within a range of 20 cm, in the physician's judgement\n4. Intolerance of dexamethasone acetate\n5. Other implanted devices that, in the judgement of the implanting physician, could interfere (mechanically or electrically) with the leadless pacemaker or with the implant procedure\n6. Allergy to the materials of the leadless pacemaker or the implant tools that are in contact with the human body\n7. Prior leadless pacemaker implant attempt\n8. Existing transvenous or leadless pacemaker, transvenous or subcutaneous ICD, or CRT device or previous extraction in which transvenous leads (full or partial) were left in the heart Note: Exception given to use temporary transvenous pacemakers\n9. CIED device extraction within the previous 72 hours or signs of active infection after CIED extraction Note: Patients with extraction due to potential systemic infection must have a blood culture. A blood culture is considered negative if there is no growth within 72 hours prior to the LivIQ implant.\n10. Planned ICD or CRT device implant\n11. Unstable angina pectoris or acute myocardial infarction within 30 days prior to enrollment\n12. Life expectancy of less than 12 months\n13. Unable to tolerate an urgent sternotomy\n14. Planned right-sided heart intervention within 30 days after implant Note: Exception given to AV nodal ablations when performed by an implanting investigator once early safety phase objectives are met\n15. Listed for or has received a heart transplantation or has a left ventricular assist device (LVAD)\n16. Participation or plan to participate in any other potentially confounding investigational drug or device trial, or any other clinical trial that may interfere with this study's treatment or protocol during the duration of the study Note: Co-enrollment in concurrent trials is only allowed when documented prior approval is obtained from BIOTRONIK\n17. Unable to attend in-person planned or emergent study site visits (e.g., frequent or extended travel plans)\n18. Pregnant or plan to become pregnant during the duration of the study\n\nAVS Sub-Study Inclusion Criteria:\n\nAfter consenting to the main study, patients potentially eligible for the AVS Sub-Study must meet these additional criteria:\n\n1. Willing and able to perform the requested procedures for the AVS assessments\n2. Current or history of AV block Note: This includes patients with any degree or type of AV block, irrespective of related symptoms and relevance of the AV block for the underlying pacemaker indication\n\nAVS Sub-Study Exclusion Criteria:\n\nAfter consenting to the main study, patients potentially eligible for the AVS Sub-Study must not meet the following criterion:\n\n1\\. Permanent AF",{"count":96,"type":21},325,[62],"The objective of this Investigational Device Exemption trial is to confirm the safety and performance of the LivIQ leadless pacemaker system, in patients with a Class I or II indication for ventricular pacing (VVI\u002FVDD) according to applicable guidelines. An integrated atrioventricular synchrony sub-study (AVS) is specifically designed to evaluate the AVS performance of the LivIQ system.",[100,30,101,102],"Leadless Pacemaker","AV Block","Cardiac Rhythm Disorder",[104],"leadless pacemaker","2026-06-17",{"date":107,"type":40},"2026-06-18",{"date":109,"type":40},"2026-03-16",{"date":111,"type":21},"2028-04",{"name":113,"class":47},"Biotronik, Inc.",13,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":23,"phases":4,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":114},"100609076","safety-performance-and-clinical-benefit-of-pacing-the-left-bundle-branch-area---post-market-clinical-follow-up-100609076","NCT07209852","Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up","Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up (SEPTA PMCF)","SEPTA PMCF","Inclusion Criteria:\n\n1. Subjects intended to undergo initial (de novo) pacing system implant using the INGEVITY+ lead in the left bundle branch area (LBBA) and a Boston Scientific single or dual- chamber pacemaker (Note: no prior attempted pacing system components);\n2. Subjects who are indicated for and will receive a Boston Scientific pacemaker system (including the single or dual chamber pacemaker and an INGEVITY+ lead in the LBBA location) for one of the following medical conditions:\n\n   1. Symptomatic paroxysmal or permanent second- or third-degree AV block,\n   2. Symptomatic bilateral bundle branch block,\n   3. Symptomatic paroxysmal or transient sinus node dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia, sinus arrest, sinoatrial \\[SA\\] block),\n   4. Bradycardia-tachycardia syndrome, to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias,\n   5. Neurovascular (vasovagal) syndromes or hypersensitive carotid sinus syndromes,\n   6. Adaptive-rate pacing for patients exhibiting chronotropic incompetence and who may benefit from increased pacing rates concurrent with increases in minute ventilation and\u002For level of physical activity.\n\n      Dual-chamber and atrial tracking modes are also indicated for patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of the following:\n   7. Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block,\n   8. VVI intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm,\n   9. Low cardiac output or congestive heart failure secondary to bradycardia;\n3. Subjects willing and capable of providing informed consent and participating in all testing and clinic visits associated with the clinical study at an approved clinical study location and at the intervals defined by protocol;\n4. Subjects who are ≥18 years of age, and of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Subjects meeting guideline indications for cardiac resynchronization therapy (CRT) in the absence of a bradycardia indication;\n2. Subjects with a known or suspected sensitivity to dexamethasone acetate (DXA);\n3. Subjects with a Mechanical Tricuspid Valve;\n4. Subjects requiring hemodialysis or peritoneal dialysis;\n5. Subject has or has had implanted any pacemaker, ICD system, including subcutaneous, transvenous or leadless systems (Note: except for temporary pacing wire at time of enrollment) or CRT system;\n6. Subjects currently on an active organ transplant list;\n7. Subject referred to or admitted for hospice care;\n8. Subjects with a documented life expectancy of less than 12 months;\n9. Subjects enrolled in any other concurrent study (unless prior approval is received from the Sponsor);\n10. Subjects who are, or plan to become pregnant during the course of the study or are breastfeeding at time of enrollment;\n11. Subjects who are unable or unwilling to comply with the follow-up schedule, including those living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome.",{"count":124,"type":21},140,"3 Years","The goal of this observational post-market clinical Follow-up study is to learn about the long-term safety, performance, and clinical benefits of pacing the left bundle branch area (LBBAP) using the INGEVITY+ pacemaker lead in patients with bradycardia who need a pacemaker.",[30,67,128,129],"Sinus Node Dysfunction","Bundle-Branch Block",[131,132,133,26,134,135,136],"Left Bundle Branch Area Pacing (LBBAP)","INGEVITY+ Lead","Pacemaker","Conduction System Pacing","Ventricular Synchrony","Post-Market Clinical Follow-up","2026-06-03",{"date":139,"type":40},"2026-06-04",{"date":141,"type":40},"2025-12-19",{"date":143,"type":21},"2029-08-31",{"name":145,"class":47},"Boston Scientific Corporation",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":87},"100511097","aveir-dr-real-world-evidence-post-approval-study-100511097","NCT05935007","Aveir DR Real-World Evidence Post-Approval Study","Aveir Dual-Chamber Leadless Pacemaker Real-World Evidence Post-Approval Study","Eligibility Criteria:\n\n* Implanted with an Aveir DR leadless pacemaker\n* Continuous enrollment in Medicare Part A and Part B for 12 months prior to implant and for -30 days after implant, except in the case of death within the 30-day period\n* Ability to link with Medicare fee-for-service data",{"count":154,"type":21},1805,"The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.",[27,157,30],"Arrythmia",[159,160,161,162,163],"bradycardia","sick sinus rhythm","pacemaker","av block","vasovagal syncope","2026-05-18",{"date":166,"type":40},"2026-05-20",{"date":168,"type":40},"2023-10-31",{"date":170,"type":21},"2030-12-31",{"name":172,"class":47},"Abbott Medical Devices",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":60,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100641046","permanent-conduction-system-pacing-versus-atrioventricular-management-for-patients-with-wide-qrs-and-patent-av-conduction-100641046","NCT07585799","Permanent Conduction System Pacing Versus Atrioventricular Management for Patients With Wide QRS and Patent AV Conduction","MORE-CSP","Inclusion Criteria:\n\n* age \\> 18 years\n* Any indication for cardiac pacing with an expected VP burden ≤ 10% after 1- month run-in period\n* Baseline wide QRS (≥150 ms) with normal PR or QRS ≥ 130 ms + PR≥230 ms\n* LVEF≥50%\n* Confirmed CSP criteria\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Pregnant woman\n* Permanent or long-lasting atrial fibrillation\n* Previous PM\u002FICD\n* Unstable angina, acute Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG), Percutaneous Coronary Angioplasty (PCI), surgical valve repair or replacement within 90 days prior enrollment\n* Moderate-severe valvular heart disease (unrepaired)\n* Already included in another clinical study that could confound the results of the present study\n* Infiltrative disease or any other genetically or acquired primary myocardial disease\n* Life expectancy \\\u003C 2 years\n* LVEF \\\u003C50%",{"count":181,"type":21},120,[62],"Intraventricular conduction delay alone or in combination with AV conduction delay is associated with a dyssynchronous activation of the ventricles and may result in LV function impairment.\n\nConduction system pacing can restore physiologic ventricular activation in the presence of intraventricular and atrioventricular conduction delays.\n\nPatients with intraventricular conduction delay alone or in combination with AV conduction delay who have a permanent pacemaker indication due to intermittent bradycardia and have predominantly intact AV conduction may benefit from continuous CSP.",[30],"2026-05-13",{"date":187,"type":40},"2026-05-15",{"date":189,"type":40},"2025-07-29",{"date":191,"type":21},"2029-01-15",{"name":193,"class":86},"Óscar Cano Pérez",3,{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":201,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":60,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100640691","impact-of-allometric-pacing-rate-on-ventricular-diastolic-function-and-cerebral-blood-flow-in-hypertensive-patients-with-sinus-node-dysfunction-100640691","NCT07589452","Impact of Allometric Pacing Rate on Ventricular Diastolic Function and Cerebral Blood Flow in Hypertensive Patients With Sinus Node Dysfunction","Inclusion Criteria:\n\n* ≥65 years of age\n* Planned implantation of a dual chamber pacemaker with physiological pacing\n* Resting sinus heart rate ≤60 bpm, or average 24 hour Holter heart rate ≤60 bpm\n* Documented history of hypertension or office systolic blood pressure ≥130 mmHg\n\nExclusion Criteria:\n\n* Diagnosis of secondary hypertension\n* Diagnosis of or possible concomitant heart failure, with ejection fraction ≤50%\n* Paroxysmal, persistent, or permanent atrial fibrillation\n* Status post CABG or PCI\n* Structural heart disease\n* Risk of ventricular tachyarrhythmia\n* Severe hepatic or renal dysfunction\n* Active acute infection\n* Inability to sign informed consent\n* Pregnancy or planned pregnancy during the study period\n* Enrollment in other clinical studies that may affect the objectives of this study","65 Years",{"count":203,"type":21},70,[62],"The study is a prospective, randomized controlled study in hypertensive patients with a bradycardia indications for pacing therapy and a plan to receive dual-chamber pacemaker. Enrolled patients will be randomized 1:1 into the control group and the allometric-pace group. In the control group, the pacing lower rate will be set to the nominal 60 bpm post a dual-chamber pacemaker implantation as frequently used in clinical practice, while in the allometric-pace group, the pacing rate will be programmed at 75 bpm based on the estimation for Chinese population with a height of 165-170 cm (also called personalized lower rate) or based on the symptom-relief per clinical assessment by the study physicians. Each patient will undergo baseline assessments and 3-month follow-up visits. At the enrollment and office visits, each patient will undergo arterial blood pressure measurement, cardiac functional assessment and cerebral blood flow measurement. At the end of the study, the study physician will adjust pacing lower rate based on patients' conditions and clinical assessments. After the completion of the study, all patients will have regular device follow-up visit, usually 6-month interval or annually.\n\nEach patient will receive the following major assessments: device performance and pacing percentages, ventricular diastolic function by doppler and echocardiography of LVEF, LVEDV, LVESV, stroke volume, cardiac output, arterial blood pressure measurements, cerebral blood flow by MRI or Echo (which one will be determined later by the study PIs), and Mini-Mental State Examination (MMSE).",[30],"NOT_YET_RECRUITING","2026-05-09",{"date":187,"type":40},{"date":187,"type":21},{"date":212,"type":21},"2028-05-31",{"name":214,"class":47},"Medtronic Cardiac Rhythm and Heart Failure",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100078039","product-performance-report-evaluate-long-term-reliability--performance-of-medtronic-marketed-cardiac-therapy-products-100078039","NCT00271180","Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products","Medtronic CRDM Product Performance Report","PPR","Subjects who meet the following inclusion criteria and do not meet any of the following exclusion criteria are eligible for enrollment.\n\nInclusion Criteria:\n\n• Subject or appropriate legal guardians provide written informed consent and\u002For authorization for access to and use of health information as required by an institution's IRB\u002FMEC\u002FREB\n\nAND one of the following must also apply:\n\n* Subject is indicated for implant or within 30 days post-implant of at least one Medtronic market-released product used for a pacing, sensing or defibrillation application\n* Subjects who participated in a qualifying study (IDE) of a Medtronic market-released product with complete implant and follow-up data and subject or appropriate legal guardian authorizes release of subject study data\n\nExclusion Criteria:\n\n* Subjects who are, or will be inaccessible for follow-up\n* Subjects with exclusion criteria required by local law (EMEA only)\n* Subjects receiving an implant of a Medtronic device at a non-participating center and the implant data and current status cannot be confirmed within 30 days after implant\n* Subjects implanted with a Medtronic device whose predetermined enrollment limit for that specific product has been exceeded",{"count":224,"type":21},20000,"The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.",[227,30,32,228],"Arrhythmia","Sinus Tachycardia",[26,28,161,230],"Sinus Bradycardia","2026-05-05",{"date":233,"type":40},"2026-05-07",{"date":235,"type":40},"1983-01",{"date":237,"type":21},"2040-12",{"name":239,"class":47},"Medtronic",320,{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100565375","ultra-high-frequency---electrocardiogram-uhf-ecg-for-the-diagnosis-of-ventricular-electrical-dyssynchrony-ved-100565375","NCT06641362","Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)","Pivotal Clinical Study of VDI's Ultra-High Frequency Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED): THE SYNC Study","SYNC","Inclusion Criteria:\n\n* Adults with bradycardia or heart failure scheduled for first time pacemaker implant (including CRT\u002FCSP) with one of the following: Bradycardia with ventricular synchrony and QRS duration \\\u003C= 110 ms, Bradycardia with LBBB, Bradycardia with RBBB, Bradycardia with other IVCD necessitating intervention, or Heart failure with LBBB\n* Understands the nature of the study and is willing to comply with all study requirements.\n* Provides written informed consent.\n* A negative pregnancy test prior to the procedure for participants of child-bearing potential.\n\nExclusion Criteria:\n\n* Complete AV block (3rd-degree AV block) without a stable escape rhythm or other circumstances where there is no measurable QRS.\n* Subjects with a previous or current pacemaker or defibrillator implant.\n* Anatomical or other conditions that may make a 12-lead ECG difficult to obtain, such as an allergy to components of the ECG pads, burns, open wounds, etc.\n* Currently enrolled in another investigational device or drug trial that has not completed the active treatment phase and\u002For would conflict with this study.\n* Other co-morbid condition(s) that could limit the participant's ability to participate in the study or to comply with study requirements or impact the scientific integrity of the study.",{"count":250,"type":21},360,"The purpose of this study is to demonstrate the safety and effectiveness of the VDI UHF-ECG System in the diagnosis of ventricular dyssynchrony when compared to the 12-lead ECG in patients with bradycardia and heart failure indicated for pacemaker implantation.",[30,32,253],"Ventricular Dysfunction","2026-05-04",{"date":231,"type":40},{"date":257,"type":40},"2025-03-18",{"date":259,"type":21},"2027-05",{"name":261,"class":47},"VDI Technologies",12,{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":271,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":60,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":87},"100636243","impact-of-optimized-pacing-strategies-on-clinical-and-hemodynamic-outcomes-in-heart-failure-patients-with-pacemaker-100636243","NCT07563153","Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker","Clinical and Hemodynamic Outcomes of OPTimized PACing StratEgies in Heart Failure Patients With Pacing Indications: Randomized-Controlled Trial (OPTPACE-HF)","OPTPACE-HF","Inclusion Criteria:\n\n* Patients with symptomatic bradycardia who meet the indication for permanent pacemaker implantation and fulfill one of the following conditions:\n\n  1. Sick sinus syndrome with or without impaired atrioventricular conduction\n  2. Persistent or permanent atrial fibrillation with slow ventricular response\n  3. Chronotropic incompetence\n* Patients diagnosed with heart failure with left ventricular ejection fraction ≥ 50% on transthoracic echocardiography with at least one of the following:\n* H2FPEF score ≥ 6 or HFA-PEFF score ≥ 5\n* N-terminal pro-B-type natriuretic peptide ≥ 300 pg\u002FmL (sinus rhythm) or ≥ 600 pg\u002FmL (atrial fibrillation)\n* Prior hospitalization for heart failure or documented use of loop diuretics for heart failure symptoms\n\nExclusion Criteria:\n\n* Patients expected to have a ventricular pacing burden ≥ 20% without sufficient capture of cardiac physiologic pacing, which includes biventricular pacing, His bundle pacing, and left bundle branch area pacing.\n\n(Sufficient cardiac physiologic pacing is defined as a paced QRS duration ≤ 140 ms.)\n\n* Patients not expected to achieve sufficient pacing dependency, defined as:\n\n  1. In sinus rhythm: baseline atrial rate \\> 60 bpm on Holter monitoring or inpatient ECG monitoring\n  2. In atrial fibrillation\u002Fflutter: baseline ventricular rate \\> 60 bpm on Holter monitoring or inpatient ECG monitoring\n* Patients with contraindications to permanent pacemaker implantation\n* Patients with moderate or greater valvular stenosis or regurgitation.\n* Patients with dyspnea not attributable to heart failure, due to uncontrolled comorbid conditions\n* Pregnant or breastfeeding women.\n* Patients who have refused active treatment.","19 Years",{"count":273,"type":21},106,[62],"This study aims to evaluate the clinical impact of an optimized pacing strategy in patients with heart failure.\n\n* Intervention: Adjustment of the pacemaker lower rate limit to an individualized, hemodynamically optimized heart rate.\n* Primary Endpoint: Heart failure symptoms, assessed by the Kansas City Cardiomyopathy Questionnaire score.\n* Hypothesis: In patients with heart failure requiring permanent pacing, an optimized pacing strategy will lead to a significant improvement in heart failure symptoms (Kansas City Cardiomyopathy Questionnaire score) at 12 months compared with the conventional pacing strategy.",[32,30],[278,159,279,280],"Heart failure","CIED","lower rate","2026-04-28",{"date":283,"type":40},"2026-05-01",{"date":285,"type":40},"2025-12-18",{"date":287,"type":21},"2028-12-31",{"name":289,"class":86},"Samsung Medical Center",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":60,"phases":299,"briefSummary":300,"conditions":301,"keywords":306,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":114},"100609654","left-bundle-branch-area-pacing-lbbap-pmcf-study-100609654","NCT07217392","Left Bundle Branch Area Pacing (LBBAP) PMCF Study","LBBAP PMCF","Inclusion Criteria:\n\n1. Meets current clinical practice guidelines for implantation of Tendril STS 2088TC or UltiPace LPA1231 lead in the Left Bundle Branch Area\n2. Are ≥ 18 years of age or age of legal consent, whichever age is greater.\n3. Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams.\n4. Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, approved by the IRB\u002FEC.\n\nExclusion Criteria:\n\n1. Patient meets a standard contraindication for lead implant including:\n\n   1. the presence of tricuspid atresia\n   2. patients with mechanical tricuspid valves\n   3. patients who are expected to be hypersensitive to a single dose of one milligram of dexamethasone sodium phosphate\n2. Patient is currently implanted with a pacemaker, ICD, or CRT-D\u002FP device\n3. Patient has had a previous unsuccessful attempt to place a lead in the LBB area\n4. Patient has planned cardiac surgical procedures or interventional measures within 3 months after implant\n5. Patient is expected to receive a heart transplant within 6 months\n6. Patient life expectancy less than 6 months\n7. Patient has the presence of another life-threatening, underlying illness separate from their cardiac disorder\n8. Patient is enrolled or planning to enroll in another clinical trial that might confound the results of the present study\n9. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.\n10. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation.",{"count":298,"type":21},200,[62],"The objective of this study is to evaluate the safety and effectiveness of LBBA pacing\u002Fsensing in patients implanted with the Tendril STS 2088TC or UltiPace LPA1231 lead through 6 months post-implant.",[30,302,32,303,304,305,134],"Right Ventricular Pacing","Atrial Fibrillation (AF)","Cardiac Disease","Left Bundle Branch Area Pacing",[307,308,309,310,159,311,312],"Right ventricular pacing","cardiac disease","heart failure","atrial fibrillation","left bundle branch area pacing","conduction system pacing","2026-04-22",{"date":315,"type":40},"2026-04-24",{"date":317,"type":40},"2025-07-24",{"date":319,"type":21},"2027-04-30",{"name":172,"class":47},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":60,"phases":329,"briefSummary":330,"conditions":331,"keywords":340,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":87},"100635703","dexmedetomidine-and-propofol-for-sedation-in-cataract-surgery-100635703","NCT07556133","Dexmedetomidine and Propofol for Sedation in Cataract Surgery.","Dexmedetomidine vs Propofol for Sedation in Cataract Surgery : a Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults undergoing cataract surgery\n\nExclusion Criteria:\n\n* Severe hepatic insufficiency\n* Third degree AV block\n* Patient refusal",{"count":20,"type":21},[62],"The goal of this prospective, randomized, single-blinded is to learn if there is an ideal sedation protocol in cataract surgery in adults.\n\nThe main questions it aims to answer are:\n\n* Does the combination of Dexmedetomidine and Propofol affect significantly Ramsay sedation scale, compared to Dexmedetomidine and compared to Propofol?\n* How does each sedation protocol affect hemodynamics? (Heart rate and blood pressure)\n* Are respiratory events more common in a certain group?\n* Is the surgeon's satisfaction similar among groups?\n* Are adverse effects (bradycardia, hypotension, nausea) more common in a certain group?\n\nResearchers will compare 3 sedation protocols : Dexmedetomidine versus Propofol versus the combination of these 2 drugs and to see if one protocol is overall superior to the others. Fentanyl will also be used in all 3 sedation protocols.\n\nParticipants will :\n\n* Receive one of these three protocols\n* Be operated for one or both eyes\n* Monitored during the whole surgery and in the recovery room\n* Be evaluated by the Ramsay sedation scale by a trained Anesthesiologist or CRNA during surgery and in the recovery room Surgeons will be asked about how much they were satisfied.",[332,333,334,335,336,337,338,30,31,339],"Sedation","Cataract","Hemodynamic","Hemodynamic Changes","Dexmedetomidine","Propofol Dosage","Fentanyl","Nausea and Vomiting",[341,333,342,343,344],"Dexmedetomidine and propofol in cataract surgery","sedation","Dexmedetomidine in cataract surgery","Sedation for cataract surgery","2026-04-21",{"date":347,"type":40},"2026-04-29",{"date":349,"type":40},"2025-11-09",{"date":351,"type":21},"2026-12-09",{"name":353,"class":86},"Saint-Joseph University",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":361,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":364,"studyType":23,"phases":4,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":87},"100631485","heartbeam-ecg-registry-100631485","NCT07501299","HeartBeam ECG Registry","Collection of ECG Recordings Using the HeartBeam 3-Lead ECG Recorder","Inclusion Criteria:\n\nUndergoing ECG as part of standard of care Able and willing to provide written informed consent\n\nExclusion Criteria:\n\nOpen chest wounds or surgery to the chest or abdomen within 30 days Inability to complete ECG acquisition with either HeartBeam device or standard 12-L ECG Unstable condition where registry participation may interfere with care",true,{"count":363,"type":21},600,"1 Day","The HeartBeam ECG Registry will collect ECG recordings acquired with the HeartBeam System with relevant clinical information in clinical settings.",[367,368,30,31,227],"Atrial Fibrillation","Atrial Flutter","2026-03-24",{"date":371,"type":40},"2026-03-30",{"date":373,"type":21},"2026-03",{"date":375,"type":21},"2028-12",{"name":377,"class":47},"HeartBeam, Inc.",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":60,"phases":388,"briefSummary":389,"conditions":390,"keywords":394,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":4},"100629048","alps-single-chamber-new-device-study-100629048","NCT07469579","ALPs Single ChambEr New Device Study","Early Feasibility Study of the Single Chamber ALPS Leadless Pacemaker System in Patients With Bradycardia","ASCEND","Inclusion Criteria:\n\n1. Male or female, ≥ 18 years of age at enrolment\n2. Subject who has a Class I or II indication for implantation of a single chamber ventricular pacemaker according to ACC\u002FAHA\u002FHRS\u002FEHRA guidelines:\n\n   1. Paroxysmal or permanent high-grade AV block in the presence of Atrial Fibrillation (AF)\n   2. Paroxysmal or permanent high-grade AV block in the absence of AF, as an alternative to dual chamber pacing, when dual chamber transvenous pacing system is considered difficult, elevated risk, or not deemed necessary for effective therapy.\n   3. Symptomatic bradycardia-tachycardia syndrome or Sinus Node Dysfunction (sinus bradycardia or sinus pauses), as an alternative to atrial or dual chamber pacing, when dual chamber transvenous pacing system is considered difficult, elevated risk, or not deemed necessary for effective therapy.\n3. Subject able and willing to undergo the study requirements and is expected to be geographically stable for the duration of the follow-up.\n4. Subject with a life expectancy of more than 24 months.\n5. Subject is able and willing to use the Home Monitor.\n6. Written informed consent to participate in the study obtained from the subject, according to local regulations, prior to initiation of any study mandated procedure.\n\nExclusion Criteria:\n\n1. Subject who is entirely pacemaker dependent (escape rhythm \\\u003C30 bpm).\n2. Subject has an existing or prior pacemaker, ICD, or CRT device implant.\n3. Subject has unstable angina pectoris or has had an acute myocardial infarction (AMI) in the 30 days prior to eligibility assessment.\n4. Subject had recent cardiovascular or peripheral vascular surgery within 30 days prior to enrollment\n5. Subject with current implantation of a neurostimulator or any other chronically implanted device which uses current in the body. Note that a temporary pacing wire is allowed.\n6. Subject with a prior intervention of the tricuspid valve, implanted vena cava filter that cannot be crossed, or left ventricular assist device (LVAD).\n7. Subject who is morbidly obese (BMI \\> 40).\n8. Subject who has a below normal BMI (BMI\\\u003C18).\n9. Subject whose femoral venous anatomy is unable to accommodate a 24 French introducer sheath or an implant on the right side of the heart (for example, due to obstructions or severe tortuosity) in the opinion of the implanter.\n10. Subject with ventricular dysfunction and LVEF ≤ 50\n11. Subject who is considered as unable to tolerate an urgent sternotomy.\n12. Subject with a known intolerance to Titanium, titanium nitride, parylene C, PEEK, platinum-iridium alloy, heparin, or sensitivity to contrast media.\n13. Subject for whom a single dose of 1.0 mg dexamethasone acetate may be contraindicated.\n14. Subject with a life expectancy of less than 24 months.\n15. Subject with significant co-morbid conditions or other conditions which, at the discretion of the PI, are deemed to prohibit study entry\n16. Subject who is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Cairdac study manager.\n17. Pregnant woman, or woman of childbearing potential and who is not on a reliable form of birth control.\n18. Subject with exclusion criteria required by local law (e.g. age, breast feeding, etc.).",{"count":387,"type":21},15,[62],"Prospective, non-randomized, multi-center, international study designed to evaluate the initial safety and performance of the ALPS leadless pacemaker when used in patients with bradycardia.",[391,392,30,101,393],"Brady-tachy Syndrome","Brady Arrythmia","Atrial Fibrillation (Paroxysmal)",[104,395,159,396,397,398,399],"leadless cardiac pacemaker","brady-tachy syndrome","AV block","Atrial Fibrilation","leadless pacing system",{"date":401,"type":40},"2026-03-18",{"date":403,"type":21},"2026-06",{"date":375,"type":21},{"name":406,"class":86},"Cairdac SA",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":60,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":87},"100520457","chronic-evaluation-of-novel-pacemaker-system-100520457","NCT06056817","Chronic Evaluation of Novel Pacemaker System","Inclusion Criteria:\n\n1. Age 18 or above\n2. Willing and capable of providing informed consent\n3. Class I or IIa indication for implantation of a single-chamber ventricular pacemaker, according to ACC\u002FAHA\u002FHRS guidelines\n4. A life expectancy of at least one year, and is a suitable candidate based on overall health and well-being\n\nExclusion Criteria:\n\n1. Patients with complete AV block or other pacemaker-dependent conditions\n2. Patients in whom a substernal device implant should be avoided:\n\n   1. Any prior sternotomy;\n   2. Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space;\n   3. Any marked sternal abnormality, such as pectus excavatum or pectus carinatum\n   4. Prior abdominal surgery in the epigastric region\n   5. Planned sternotomy\n   6. Prior or planned chest radiotherapy\n   7. Hiatal hernia that distorts mediastinal anatomy\n   8. Adhesions in the anterior mediastinal space\n   9. Severe obesity so that subxiphoid\u002Fsubsternal tunneling cannot be safely performed\n3. Patients with severe RV dilation, gross hepatosplenomegaly, or severe obesity such that subxiphoidal\u002Fsubsternal tunneling cannot be safely performed\n4. Patients with a class III indication for a permanent pacemaker\n5. Patients with decompensated heart failure not due to bradycardia and expected to worsen with chronic RV pacing\n6. Patients with an implanted cardiac pacemaker, cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device, or planned implantation of a cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device\n7. Patients with a current or planned implantation of a substernal device, or any implanted device that would interfere with the implantation or operation of a substernal device\n8. Patients who have previously undergone an open-heart surgical procedure.\n9. Patients with an active infection\n10. Patient on chronic oral anticoagulation which cannot be temporarily discontinued for surgery\n11. Patients with a condition in which pericardial pacing would be difficult or impossible, such as acute pericarditis, chronic pericardial effusion or pericardial thickening or calcification, cardiac tamponade, or chronic restrictive pericarditis\n12. Patients who have tested positive for the COVID-19 in the past 3 months, or are currently showing symptoms consistent with COVID-19\n13. Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding\n14. Subjects with a life expectancy of less than 12 months\n15. Patients who are currently enrolled or planning to participate in any concurrent clinical study with an investigational therapy\n16. Patients with decompensated heart failure expected to worsen with chronic RV pacing\n17. Patients with COPD with oxygen dependence",{"count":414,"type":21},10,[62],"The primary study objective is to evaluate the feasibility, initial clinical safety and potential effectiveness of the Calyan Pacemaker system.",[418,30],"Ventricular Pacing With Rate Response",{"date":401,"type":40},{"date":421,"type":21},"2026-04-01",{"date":423,"type":21},"2027-12-31",{"name":425,"class":47},"Calyan Technologies",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":383,"acronym":384,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":60,"phases":433,"briefSummary":389,"conditions":434,"keywords":435,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":453,"leadSponsor":454,"locationsCount":4},"100628461","alps-single-chamber-new-device-100628461","NCT07461935","ALPs Single ChambEr New Device","Inclusion Criteria:\n\n1. Male or female, ≥ 18 years of age at enrolment\n2. Subject who has a Class I or II indication for implantation of a single chamber ventricular pacemaker according to ACC\u002FAHA\u002FHRS\u002FEHRA guidelines:\n\n   * Paroxysmal or permanent high-grade AV block in the presence of Atrial Fibrillation (AF)\n   * Paroxysmal or permanent high-grade AV block in the absence of AF, as an alternative to dual chamber pacing, when dual chamber transvenous pacing system is considered difficult, elevated risk, or not deemed necessary for effective therapy.\n   * Symptomatic bradycardia-tachycardia syndrome or Sinus Node Dysfunction (sinus bradycardia or sinus pauses), as an alternative to atrial or dual chamber pacing, when dual chamber transvenous pacing system is considered difficult, elevated risk, or not deemed necessary for effective therapy.\n3. Subject able and willing to undergo the study requirements and is expected to be geographically stable for the duration of the follow-up.\n4. Subject with a life expectancy of more than 24 months.\n5. Subject is able and willing to use the Home Monitor.\n6. Written informed consent to participate in the study obtained from the subject, according to local regulations, prior to initiation of any study mandated procedure.\n\nExclusion Criteria:\n\n1. Subject who is entirely pacemaker dependent (escape rhythm \\\u003C30 bpm).\n2. Subject has an existing or prior pacemaker, ICD, or CRT device implant.\n3. Subject has unstable angina pectoris or has had an acute myocardial infarction (AMI) in the 30 days prior to eligibility assessment.\n4. Subject had recent cardiovascular or peripheral vascular surgery within 30 days prior to enrollment\n5. Subject with current implantation of a neurostimulator or any other chronically implanted device which uses current in the body. Note that a temporary pacing wire is allowed.\n6. Subject with a prior intervention of the tricuspid valve, implanted vena cava filter that cannot be crossed, or left ventricular assist device (LVAD).\n7. Subject who is morbidly obese (BMI \\> 40).\n8. Subject who has a below normal BMI (BMI\\\u003C18).\n9. Subject whose femoral venous anatomy is unable to accommodate a 24 French introducer sheath or an implant on the right side of the heart (for example, due to obstructions or severe tortuosity) in the opinion of the implanter.\n10. Subject with ventricular dysfunction and LVEF ≤ 50\n11. Subject who is considered as unable to tolerate an urgent sternotomy.\n12. Subject with a known intolerance to Titanium, titanium nitride, parylene C, PEEK, platinum-iridium alloy, heparin, or sensitivity to contrast media.\n13. Subject for whom a single dose of 1.0 mg dexamethasone acetate may be contraindicated.\n14. Subject with a life expectancy of less than 24 months.\n15. Subject with significant co-morbid conditions or other conditions which, at the discretion of the PI, are deemed to prohibit study entry\n16. Subject who is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented preapproval is obtained from the Cairdac study manager.\n17. Pregnant woman, or woman of childbearing potential and who is not on a reliable form of birth control.\n18. Subject with exclusion criteria required by local law (e.g. age, breast feeding, etc.).",{"count":414,"type":21},[62],[30,391,101,303],[104,436,30,437,397,367,161,395,399,438,439,440,441,442,443,444,445,446,447,448],"ventricular leadless pacemaker","Brady-tachy syndrome","delivering leadless system","permanent leadless pacemaker","single chamber leadless pacemaker","single chamber leadless pacing therapy","VVI","autonomous leadless pacing system","piezoelectric energy harvester","VOO","home monitor","home monitoring","remote monitoring","2026-03-09",{"date":451,"type":40},"2026-03-10",{"date":403,"type":21},{"date":375,"type":21},{"name":406,"class":86},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":60,"phases":465,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":477},"100494536","novel-setup-algorithm-for-cardiac-neuromodulation-therapy-100494536","NCT05719454","Novel Setup Algorithm for Cardiac Neuromodulation Therapy","Clinical Feasibility of a Novel Setup Algorithm for BackBeat Medical's Cardiac Neuromodulation Therapy (CNT) Pacing Signals","CS-10","Inclusion Criteria:\n\n* Subject is ≥ 18 years of age\n* Subject requires implantation or replacement of a dual chamber pacemaker or requires an upgrade from a single chamber to a dual chamber pacemaker.\n* Subject has stable (for prior 1 month) hypertension treatment with 1, 2 or 3 antihypertensive drugs, which is planned to be maintained without changes for a period of at least 2 months post implant.\n* Subject has an office systolic blood pressure (oSBP) ≥140 and \\\u003C180 mmHg\n* At 4 weeks from device implant, subject has an average 24-Hour ambulatory systolic blood pressure (aSBP) ≥130 mmHg and \\\u003C170 mmHg and an office blood pressure (oSBP) ≥140 and \\\u003C180 mmHg.\n* Subject is willing and able to comply with study visits and procedures\n* Subject is willing to adhere to the prescribed baseline antihypertension medical regimen for the duration of the study.\n\nExclusion Criteria:\n\n* 1\\. Subject has a known secondary cause of HTN (e.g. renal vascular disease, hyperthyroidism, hyperaldosterone and pheochromocytoma)\n* Subject has permanent atrial fibrillation\n* Subject has intermittent paroxysmal atrial fibrillation\u002Fflutter with significant burden (i.e., \\>10% atrial fibrillation\u002Fflutter beats if available.\n* Subject has an ejection fraction \\\u003C50%\n* Subject has a drop of \\> 15% (absolute) in ejection fraction from baseline to week 4\n* Subject has symptoms of heart failure, NYHA Class II or greater\n* Subject has mitral regurgitation ≥2+, aortic stenosis with valve area \\\u003C1.0 cm2 , or is expected to need a valve repair or replacement.\n* Subject has a history of stroke or TIA within 12 months or any prior stroke with a residual neurological deficit (modified Rankin Score \\>2+)\n* Subject experienced myocardial infarction (MI) within 3 months prior to enrolment\n* Subject had a cardiovascular interventional procedure or cardiovascular surgery within 6 months prior to enrolment\n* Subject has hypertrophic cardiomyopathy, restrictive cardiomyopathy or interventricular septal thickness ≥15 mm\n* Subject is on dialysis\n* Subject has estimated glomerular filtration rate (GFR) \\\u003C30 ml\u002Fmin\u002F1.73m²\n* Subject has significant (\\>50% occlusion of left or right carotid artery) carotid artery stenosis\n* Subject has a history of clinically significant untreated ventricular tachyarrhythmia or has experienced sudden cardiac arrest\n* Subject has an active device-based treatment for hypertension\n* Subject has an existing active cardiac device or neurostimulator (e.g., ICD, spinal cord stimulator)\n* Subject has Type I Diabetes\n* Subject is a member of a vulnerable population (e.g., prisoners, pregnant or lactating women, mentally disabled)\n* Subject has the possibility of becoming pregnant during the conduct of the study and is not willing to use a means of contraception during the study\n* Subject cannot or is unwilling to provide informed consent",{"count":464,"type":21},30,[62],"After meeting all inclusion\u002Fexclusion criteria, subjects on standard pacing with the Moderato® or Moderato Plus Implantable Pulse Generator (IPG) will be subjected to two set-up sessions for the CNT algorithm: at week 4 and at week 6 post implant. At the end of these visits, subjects will undergo a 24 ambulatory blood pressure recording after which CNT will be automatically turned OFF and standard pacing will resume.\n\nThe ambulatory data will provide the basis for a lasting CNT programming by week 8. Follow up visits will be scheduled after 3, 6, and 12 months.",[468,30],"Hypertension","2026-03-06",{"date":449,"type":40},{"date":472,"type":40},"2023-06-21",{"date":474,"type":21},"2028-02-28",{"name":476,"class":47},"BackBeat Medical Inc",7,{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":486,"targetDuration":487,"studyType":23,"phases":4,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":87},"100449072","pacemaker-based-long-term-monitoring-of-sleep-apnea-100449072","NCT05127720","Pacemaker-based Long-term Monitoring of Sleep Apnea","Schrittmacher-basiertes Schlafapnoe Langzeit-Monitoring","ACaSA","Inclusion Criteria:\n\n* implanted Microport TEO SR\u002FDR or BOREA SR\u002FDR or ALIZEA SR\u002FDR pacemaker device\n* signed informed consent\n\nExclusion Criteria:\n\n* any contraindication to perform a cardiac CT examination\n* eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n* allergy against CT contrast medium\n* hyperthyreoism\n* inability of the patient to understand the study purpose and plan\n* inability of the patient to perform baseline examinations\n* pregnancy or breast-feeding; women with childbearing potential\n* estimated life expectancy below one year",{"count":20,"type":21},"20 Years","This is a prospective, non-interventional cohort study. It tests the hypothesis that\n\n* Pacemaker-derived monitoring of sleep-related breathing disorders and\u002For daily physical activity predicts clinical outcome.\n* Autonomic imbalance defined by an increased periodic repolarisation dynamics (PRD) predicts clinical outcome in pacemaker patients.\n* Autonomic imbalance defined by an increased periodic repolarisation dynamics (PRD) predicts the occurrence of device-detected atrial fibrillation and\u002For device-detected sleep apnea.\n* Enviromental factors such as ambient temperature, humidity, precipitation, air pressure impacts device-detected atrial fibrillation and\u002For device-detected sleep apnea.\n* Variation of night-to-night device-detected sleep apnea shows sex-specific patterns and impacts device-detected atrial fibrillation burden, ventricular pacing rate in sick sinus syndrome and clinical outcomes.\n* Burden \u002F variation of device-detected sleep apnea and\u002For device-detected atrial fibrillation correlates with the incidence and severity of common ophthalmologic diseases.",[30],"2026-02-20",{"date":492,"type":40},"2026-02-24",{"date":494,"type":40},"2021-11-30",{"date":496,"type":21},"2041-12-31",{"name":498,"class":86},"Medical University Innsbruck",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":60,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":4},"100619283","safety-and-performances-of-the-linea-cardiac-pacing-lead-optimized-for-the-implantation-in-interventricular-septum-100619283","NCT07342608","Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum","STARLIGHT","Inclusion criteria (phase I and II):\n\n* Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)\n* Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM\n* Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area\n* Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated\n\nExclusion criteria (phase I and II):\n\n* Patient planned for a device upgrade, or a device or a lead replacement\n* Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy\n* Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%\n* Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)\n* Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)\n* Patient with a life expectancy of less than 2 years\n* Minor age patient (i.e. under 18 years of age)\n* Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation\n* Non-menopausal women",{"count":507,"type":21},450,[62],"The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.",[30,305,511],"Left Bundle Branch Pacing","2026-02-13",{"date":514,"type":40},"2026-02-17",{"date":516,"type":21},"2026-03-31",{"date":518,"type":21},"2030-04-30",{"name":520,"class":47},"MicroPort CRM",{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":60,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":87},"100622015","lll-vs-sdl-for-lbbp-a-non-inferiority-rct-100622015","NCT07378124","LLL vs. SDL for LBBP: A Non-inferiority RCT","Efficacy and Safety Comparison of Lumenless Lead Versus Stylet-driven Lead in Intraoperative Application of Left Bundle Branch Pacing Guided by Continuous Pacing Monitoring With S-V Dissociation as the Primary Outcome: A Non-inferiority, Multicenter, Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Symptomatic sick sinus syndrome (SSS);\n* Complete or advanced atrioventricular block (AVB);\n* Patients with heart failure complicated by left bundle branch block (LBBB) and biventricular dyssynchrony;\n* Patients with atrial fibrillation (AF) complicated by refractory rapid ventricular rate who are scheduled for atrioventricular node ablation and permanent pacemaker implantation;\n* Other patients who meet the indications for dual-chamber pacemaker implantation as specified in current guidelines\n\nExclusion Criteria:\n\n* Patients who are ineligible for transvenous cardiac pacemaker implantation due to anatomical abnormalities, infections, or other factors;\n* Patients with existing implantable cardiac electronic devices (ICEDs);\n* Patients who opt for right-sided venous access for any reason;\n* Patients with an expected survival of less than 1 year;\n* Patients who have been enrolled in other clinical trials related to implantable cardiac electronic devices within 3 months prior to enrollment in this study.",{"count":529,"type":21},288,[62],"Left Bundle Branch Pacing (LBBP) has emerged as one of the most commonly used physiological pacing modalities in clinical practice. However, the key determinants of procedural success lie in the accurate intraoperative identification of proper LBB lead positioning and the prevention of cardiac perforation. Our previous research has established a methodology for Lumenless Lead (LLL) implantation under the guidance of continuous pacing monitoring, and this methodology has been further adapted for Stylet-driven Lead (SDL) implantation. The present study is designed as a multicenter, randomized controlled trial, aiming to compare the differences in efficacy and safety between LLL and SDL during LBBP procedures guided by continuous pacing monitoring, with the presence of S-V dissociation serving as the criterion for confirming optimal LBB lead positioning.",[30,533],"Conduction Block, Atrioventricular","2026-01-31",{"date":536,"type":40},"2026-02-03",{"date":538,"type":21},"2026-01-24",{"date":423,"type":21},{"name":541,"class":86},"Ningbo No.2 Hospital",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":550,"maxAge":57,"enrollmentInfo":551,"targetDuration":4,"studyType":60,"phases":552,"briefSummary":555,"conditions":556,"keywords":559,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":87},"100609984","phase-2-comparison-of-supra-vs-infra-inguinal-fascia-iliaca-blocks-for-spinal-positioning-and-analgesia-in-lower-limb-surgery-100609984","NCT07221682","Comparison of Supra vs Infra Inguinal Fascia Iliaca Blocks for Spinal Positioning and Analgesia in Lower Limb Surgery","Comparison For Ease Of Spinal Positioning & Duration Of Post-Op Analgesia Between Ultrasound Guided Supra-Inguinal Fascia Iliaca Block Vs Ultrasound Guided Infra-Inguinal Fascia Iliaca Block In Patients Undergoing Thigh & Knee Surgeries","27G","Inclusion Criteria:\n\n1. Both Genders (Male \u002FFemale).\n2. Age between 30 years to 60 years.\n3. ASA Class I, II, III.\n\nExclusion Criteria:\n\n1. Patient refusal\n2. Other distracting painful pathology\n3. Any contraindication to Spinal Anesthesia or peripheral nerve blocks\n4. Coagulopathic disorders\n5. Patients with significant cognitive impairment\n6. Patients with no pain while sitting by themselves without any support\n7. H\u002FO polytrauma involving other limbs\n8. H\u002FO allergy to the drugs used in study","30 Years",{"count":59,"type":21},[553,554],"PHASE2","PHASE3","Severe pain associated with thigh and knee fractures makes the positioning for regional anesthesia a challenge. Different modalities to make patient pain free for spinal positioning, post op analgesia and patient satisfaction including supra-inguinal fascia iliaca block (S-FIB) and infra-inguinal fascia iliaca blocks (I-FIB) have been studies. The aim of this study is to compare two blocks in patients undergoing thigh and knee surgeries.\n\nA randomized controlled trial study design will be used and 60 patients fulfilling the inclusion criteria will be included. The patients will be divided into 2 groups by simple random sampling. Group A (S-FIB) (n = 30, those who will receive 30 ml of 0.125% bupivacaine) and Group B (I-FIB) (n = 30, those who will receive 30 ml of 0.125% bupivacaine). Depending on the allotted group, patients will be given the block under the guidance of ultrasound in the preoperative area. After block patients will be assessed for ease of spinal positioning using EOSP Scale, postoperative duration of analgesia and patient satisfaction using Likert Scale and data will be recorded on prescribed proforma.\n\nAll the findings will be noted in a specially designed proforma by the researcher. All the data collected will be entered and analyzed. Quantitative variables will be presented with mean ± SD. Independent sample t-test for duration of postoperative analgesia. Qualitative variables such as ease of spinal positioning and gender will be presented with Chi-Square. A p-value equal to or less than 0.05 will be considered significant.",[557,30,558],"Post Operative Analgesia","Hypotension Drug-Induced",[560,561,562,563],"S-FICB","I-FICB","ASA","EOSP","2026-01-28",{"date":566,"type":40},"2026-01-29",{"date":568,"type":40},"2024-05-06",{"date":570,"type":21},"2027-01-01",{"name":572,"class":573},"Sahiwal medical college sahiwal","OTHER_GOV",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":87},"100286410","his-bundle-pacing-in-bradycardia-and-heart-failure-100286410","NCT03008291","His Bundle Pacing in Bradycardia and Heart Failure","Inclusion Criteria:\n\nHF Group\n\n* Clinically recommended to undergo PM, CRT-P, or CRT-D implantation or HIBP\u002FLBAP (including HIBP\u002FLBAP for patients with HF, for patients who have failed CRT implant or patients who are CRT non-responders)\n* Any QRS duration\n* LVEF ≤ 50%\n\nAV Block\u002FBradycardia Group\n\n* Recommended to undergo dual chamber pacemaker implantation\n* Any AV block or Sinus Bradycardia\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant",{"count":581,"type":21},80,"Participants in this study will either have heart failure (HF) and are scheduled to undergo pace maker (PM) implantation, cardiac resynchronization therapy pacemaker (CRT-P), cardiac resynchronization therapy defibrillator (CRT-D) implantation, His bundle pacing (HIBP) or left bundle area pacing (LBAP) (including HIBP\u002FLBAP for patients with HF, for patients who have failed CRT implant or patients who are CRT non-responders), or have atrioventricular (AV) block or bradycardia and are scheduled to undergo dual chamber pacemaker implantation. In this study additional heart rhythm measurements will be collected during the implant procedure to better understand how His bundle and\u002For parahisian pacing (HISP) effects electrical conduction in the hearts of patients with HF or AV block.\n\nThe hypothesis is that His bundle or parahisian pacing (HISP) and left bundle area pacing (LBAP) may normalize atrioventricular (AV) conduction with a narrow combination of the Q wave, R wave and S wave (QRS complex) in functional bundle branch block or conduction delay in patients with heart failure (HF).",[30,32],"2025-12-22",{"date":586,"type":40},"2025-12-24",{"date":588,"type":4},"2016-10",{"date":590,"type":21},"2026-12",{"name":592,"class":86},"Yong-Mei Cha",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":361,"sex":17,"minAge":18,"maxAge":599,"enrollmentInfo":600,"targetDuration":4,"studyType":60,"phases":602,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":87},"100615283","phase-2-comparative-analysis-of-dexmedetomidine-and-dexamethasone-as-an-adjuvant-to-05ropivacaine-on-onset-of-ultrasound-guided-supraclavicular-brachial-plexus-block-in-patients-undergoing-upper-limb-surgeries-100615283","NCT07290595","Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries","Inclusion Criteria\n\n* Patients scheduled for upper limb surgery below mid-humerus level\n* Patients aged 18 to 70 years\n* Patients with ASA class I, II and III\n* Male and non-pregnant females Exclusion Criteria\n* Patients refusal\n* Patients with pre-existing peripheral neuropathy of the upper limb\n* Patients with the Infection at block site\n* Patients with history of ischemic heart disease\n* Patients with bleeding disorder or deranged coagulation profile\n* Patients with known history of allergy to local anaesthetic or any other drugs used","70 Years",{"count":601,"type":21},66,[553,554],"To compare the efficacy of dexmedetomidine and dexamethasone as an adjuvant to 0.5%ropivacaine on onset of ultrasound guided supraclavicular brachial plexus block in patients undergoing upper limb surgeries.\n\nRopivacaine hydrochloride, a long acting local anesthetic, is commonly used for supraclavicular block owing to its favorable safety profile especially in terms of minimal cardiotoxicity and less motor block. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist, enhances the quality of supraclavicular block by providing sedation and analgesia while potentially prolonging the duration of block through hyperpolarization of nerve fibers. While, Dexamethasone, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, prolongs duration of analgesia by reducing perineural inflammation and inhibiting nociceptive signal transmission. Supraclavicular brachial plexus block offers dense anesthesia for surgical procedures at or distal to the elbow with relatively high success rate, once described as \"spinal of the arm\". Moreover, supraclavicular brachial plexus block is an excellent alternative to general anesthesia in upper limb surgeries.",[557,30,605,606],"Hypotension","Upper Limb Surgeries","2025-12-20",{"date":609,"type":40},"2025-12-23",{"date":611,"type":40},"2025-01-13",{"date":613,"type":21},"2026-03-12",{"name":572,"class":573},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":622,"maxAge":623,"enrollmentInfo":624,"targetDuration":4,"studyType":60,"phases":626,"briefSummary":627,"conditions":628,"keywords":631,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":87},"100462214","the-effect-of-womb-recordings-on-maturation-of-respiratory-control-in-preterm-infants-100462214","NCT05298748","The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants","Womb Recordings and Respiratory Control Maturation in Neonates","Inclusion Criteria:\n\n* preterm infants 29-33 weeks gestational age at birth\n* 34 weeks corrected age\n* off respiratory support \\>1.5 lpm\n\nExclusion Criteria:\n\n* on respiratory support \\>1.5 lpm\n* congenital anomalies","1 Week","5 Weeks",{"count":625,"type":21},34,[62],"The aim of this proposal is to characterize the acute effect of early postnatal sound exposure on neuronal maturation of the respiratory control regions of the brain in preterm infants.",[629,630,30],"Apnea of Prematurity","Intermittent Hypoxemia",[632],"apnea, intermittent hypoxemia, bradycardia, audio recording","2025-12-04",{"date":635,"type":40},"2025-12-05",{"date":637,"type":40},"2022-09-16",{"date":639,"type":21},"2026-11",{"name":641,"class":86},"Case Western Reserve University",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":12,"sex":17,"minAge":271,"maxAge":4,"enrollmentInfo":649,"targetDuration":4,"studyType":60,"phases":651,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":87},"100612987","evaluation-of-a-single-lead-ecg-patch-based-telemetry-system-for-in-hospital-monitoring-100612987","NCT07260721","Evaluation of a Single-lead ECG Patch-based Telemetry System for In-hospital Monitoring","Investigator-initiated Trial to Evaluate the Performance and Utility of a Single-lead Electrocardiogram Patch-based Telemetry System in Patients Requiring In-hospital Telemetry Electrocardiogram Monitoring During Hospitalization","Inclusion Criteria:\n\n* Adults aged 19 years or older who provide written informed consent for participation.\n* Patients requiring in-hospital telemetry electrocardiogram monitoring during hospitalization.\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergic reaction to adhesives or hydrogel.\n* Presence of skin wounds at the intended application site of the investigational device.\n* Implanted cardiac electronic devices such as pacemakers, ICDs, or other CIEDs\n* Current or past history of skin cancer, rash, dermatologic disorders, keloid formation, or skin injury.\n* Any condition judged by the investigator to increase risk or make participation inappropriate.\n* Cognitive impairment that precludes understanding of study information or voluntary consent.",{"count":650,"type":21},100,[62],"\"This investigator-initiated, prospective, single-center clinical study evaluates the performance and clinical utility of a single-lead electrocardiogram (ECG) patch-based telemetry system for hospitalized patients who require in-hospital telemetry ECG monitoring. The system integrates real-time centralized surveillance (MEMO-Cue) with post-hoc analytic review (MEMO-Care) using ECG signals recorded by the MEMO Patch M, aiming to enable timely recognition of clinically important arrhythmias and to inform treatment decisions under routine inpatient conditions.\n\nAdults (≥19 years) indicated for continuous ECG monitoring during admission are enrolled after written informed consent, with a planned sample size of 100 to yield approximately 90 evaluable participants (10% anticipated dropout). The design does not include randomization or blinding. Study procedures include a screening visit (eligibility and baseline data), an inpatient monitoring period of at least 12 hours and up to 8 days with simultaneous MEMO-Cue monitoring and MEMO Patch M recording, and an end-of-visit assessment when MEMO-Care analytic results become available. Concomitant therapies deemed clinically necessary are permitted and documented, and adverse events are prospectively assessed.\n\nClinical utility endpoints quantify care impact and timeliness: (1) rate of treatment plan changes (e.g., initiation or modification of anticoagulants or antiarrhythmic drugs, cardioversion scheduling, device implantation, or other actions); (2) time to recognition (days) of major arrhythmias-atrial fibrillation (AF), ventricular tachycardia (VT), pause, ventricular premature complex (VPC), and supraventricular tachycardia (SVT)-based on MEMO-Cue alarms or MEMO-Care results with objective confirmation; (3) reduction ratio in recognition time when identified earlier by MEMO-Cue versus MEMO-Care; and (4) proportion of participants with shortened recognition time by MEMO-Cue.\n\nClinical performance endpoints assess detection characteristics and agreement between MEMO-Cue alarms and MEMO-Care findings: (1) clinical sensitivity (true positive \u002F \\[true positive + false negative\\]); (2) precision, i.e., positive predictive value (true positive \u002F \\[true positive + false positive\\]); and (3) positive concordance rate (proportion of MEMO-Care-detected arrhythmias alerted by MEMO-Cue). Safety is captured as treatment-emergent adverse events after device application, including device-related skin reactions, detachment, or signal dropouts, with severity graded per NCI-CTCAE v5.0 and relationship to device recorded.\n\nBy characterizing real-time patch-based telemetry alongside analytic review and its influence on diagnostic timing and management, the study aims to generate practical evidence supporting feasibility, reliability, and workflow compatibility of single-lead patch telemetry for in-hospital ECG monitoring.",[654,367,655,656,30,657,658,659],"Arrhythmias","Ventricular Tachycardia","Supraventricular Tachycardia","Telemetry","Patient Monitoring","Hospitalization","2025-12-01",{"date":662,"type":40},"2025-12-03",{"date":664,"type":21},"2025-12",{"date":666,"type":21},"2026-09",{"name":668,"class":86},"Yonsei University"]